Kezar Life Sciences (NASDAQ:KZR – Get Free Report) and Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Earnings and Valuation
This table compares Kezar Life Sciences and Tectonic Therapeutic”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kezar Life Sciences | N/A | N/A | -$56.03 million | ($6.17) | -1.18 |
| Tectonic Therapeutic | N/A | N/A | -$74.15 million | ($4.46) | -6.12 |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Kezar Life Sciences and Tectonic Therapeutic, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kezar Life Sciences | 2 | 4 | 0 | 0 | 1.67 |
| Tectonic Therapeutic | 1 | 0 | 5 | 1 | 2.86 |
Kezar Life Sciences currently has a consensus price target of $6.00, indicating a potential downside of 17.70%. Tectonic Therapeutic has a consensus price target of $79.83, indicating a potential upside of 192.54%. Given Tectonic Therapeutic’s stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Kezar Life Sciences.
Institutional & Insider Ownership
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 10.4% of Kezar Life Sciences shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Kezar Life Sciences and Tectonic Therapeutic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kezar Life Sciences | N/A | -55.42% | -47.87% |
| Tectonic Therapeutic | N/A | -32.33% | -30.92% |
Volatility & Risk
Kezar Life Sciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.27, indicating that its stock price is 227% more volatile than the S&P 500.
Summary
Tectonic Therapeutic beats Kezar Life Sciences on 9 of the 12 factors compared between the two stocks.
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
About Tectonic Therapeutic
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
